Cargando…

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients

PURPOSE: For patients with rheumatoid arthritis (RA) who do not respond or lose response to anti-tumor necrosis factor (TNF) biologics, switching to a different anti-TNF can be an effective means to manage symptoms and disease progression. This study examined the utilization and effectiveness of int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bray, Vance J., Broadwell, Aaron, Baraf, Herbert S. B., Black, Shawn, Brady, Brenna L., Tkacz, Joseph, Yarngo, Lorraine, DeHoratius, Raphael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131122/ https://www.ncbi.nlm.nih.gov/pubmed/30054896 http://dx.doi.org/10.1007/s40268-018-0240-1

Ejemplares similares

Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab
por: Ellis, Lorie A, et al.
Publicado: (2019)

Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age
por: Tesser, John, et al.
Publicado: (2019)

Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy
por: Gaylis, Norman B, et al.
Publicado: (2017)

Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study
por: Broadwell, Aaron, et al.
Publicado: (2023)

Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
por: Bingham, Clifton O., et al.
Publicado: (2023)

Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
por: Tesser, John, et al.
Publicado: (2022)

Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept
por: Dehoratius, Raphael J., et al.
Publicado: (2018)

Ethnographic Observational Study of the Biologic Initiation Conversation Between Rheumatologists and Biologic‐Naive Rheumatoid Arthritis Patients
por: Kottak, Nicholas, et al.
Publicado: (2018)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

Golimumab for Rheumatoid Arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
por: Wakabayashi, Hiroki, et al.
Publicado: (2016)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis
por: Curtis, Jeffrey R., et al.
Publicado: (2019)

Dose Adjustment of Methotrexate Administered Concomitantly with Golimumab for Rheumatoid Arthritis in Japanese Real-World Clinical Settings
por: Yamairi, Fumiko, et al.
Publicado: (2020)

Adalimumab/golimumab/infliximab: SARS-CoV-2 pneumonia: 3 case reports
Publicado: (2021)

Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials
por: Gensler, L. S., et al.
Publicado: (2020)

Effectiveness of Golimumab in Clinical Management of Patients with Rheumatoid Arthritis
por: Shono, Eisuke
Publicado: (2013)

Assessment of Rheumatoid Arthritis Quality Process Measures and Associated Costs
por: Brady, Brenna L., et al.
Publicado: (2017)

Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis
por: Kanbe, Katsuaki, et al.
Publicado: (2015)

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
por: Petryszyn, Pawel, et al.
Publicado: (2020)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
por: Husni, M. Elaine, et al.
Publicado: (2022)

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis
por: Nemoto, Tetsuya, et al.
Publicado: (2020)

Effectiveness and Safety of Golimumab for Patients ≥75 Years Old with Rheumatoid Arthritis
por: Kurosawa, Yoichi, et al.
Publicado: (2022)

Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence
por: Iannone, Florenzo, et al.
Publicado: (2022)

Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

Erratum for Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis
por: Nemoto, Tetsuya, et al.
Publicado: (2021)

Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis
por: Husni, M. Elaine, et al.
Publicado: (2020)

Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

Infliximab in the treatment of rheumatoid arthritis
por: Perdriger, A
Publicado: (2009)

Increasing rate of diagnosed childhood mental illness in the United States: Incidence, prevalence and costs
por: Tkacz, Joseph, et al.
Publicado: (2021)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
por: Deodhar, Atul, et al.
Publicado: (2015)

Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Golimumab in unresponsive ulcerative colitis
por: Lippert, Elisabeth, et al.
Publicado: (2014)

Golimumab for the treatment of ulcerative colitis
por: Löwenberg, Mark, et al.
Publicado: (2014)

Golimumab in the treatment of ulcerative colitis
por: Cunningham, Georgina, et al.
Publicado: (2019)

Golimumab for the treatment of ulcerative colitis
por: Flamant, Mathurin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hta7r3a8mp24co6nlkilonptar